APLS · Categories · Form 4

APLS - SEC Form 4 insider transactions

Apellis Pharmaceuticals Inc. (APLS) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for APLS

• 24d
  Director Dunlop A. Sinclair returned 20,311 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  VP/Chief Accounting Officer Chopas James George was granted 38,244 shares and returned 76,650 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Director Dolsten Mikael returned 14,312 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Chief Research and Development Meltzer Leslie returned 174,854 shares to the company and was granted 67,830 shares, closing all direct ownership in the company (SEC Form 4) to cover withholding tax

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Director Fonteyne Paul R. returned 24,188 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Chief Financial Officer Sullivan Timothy Eugene was granted 159,080 shares and returned 270,413 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Director Machiels Alec returned 20,311 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Chief Scientific Officer Deschatelets Pascal was granted 90,040 shares and returned 135,445 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Director Chan Gerald returned 24,188 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Chief Technical Officer Nicholson Nur was granted 133,364 shares and returned 221,303 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Director Walbert Keli returned 16,293 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Chief Business & Strat Officer Delong Mark Jeffrey was granted 115,165 shares and returned 186,543 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Director O'Brien Stephanie Monaghan returned 24,188 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Chief People Officer Boucher Kelley was granted 45,219 shares and returned 173,023 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Director Wheeler Craig A returned 23,071 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  General Counsel Watson David O. was granted 153,737 shares and returned 267,033 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Chief Executive Officer Francois Cedric was granted 524,786 shares and returned 875,644 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 24d
  Chief Medical Officer Baumal Caroline was granted 67,646 shares and returned 118,953 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 37d
  Chief Medical Officer Baumal Caroline gifted 900 shares, decreasing direct ownership by 1% to 86,525 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 48d
  SEC Form 4 filed by Sullivan Timothy Eugene

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 60d
  SEC Form 4 filed by O'Brien Stephanie Monaghan

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 86d
  Chief Executive Officer Francois Cedric gifted 64,869 shares and received a gift of 64,869 shares, decreasing direct ownership by 13% to 425,968 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 96d
  Director Dolsten Mikael was granted 14,312 shares (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 114d
  Chief Business & Strat Officer Delong Mark Jeffrey sold $8,153 worth of shares (368 units at $22.15), decreasing direct ownership by 0.32% to 114,591 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 122d
  Chief Executive Officer Francois Cedric exercised 8,840 shares at a strike of $3.76, increasing direct ownership by 2% to 490,837 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 128d
  Chief People Officer Boucher Kelley was granted 30,146 shares, increasing direct ownership by 31% to 127,804 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 128d
  VP/Chief Accounting Officer Chopas James George was granted 16,150 shares, increasing direct ownership by 32% to 65,955 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 128d
  Chief Business & Strat Officer Delong Mark Jeffrey was granted 36,606 shares, increasing direct ownership by 47% to 114,959 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 128d
  Chief Scientific Officer Deschatelets Pascal was granted 25,840 shares, increasing direct ownership by 2% to 1,177,222 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 128d
  Chief Research and Development Meltzer Leslie was granted 45,220 shares, increasing direct ownership by 73% to 107,024 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 128d
  Chief Technical Officer Nicholson Nur was granted 45,220 shares, increasing direct ownership by 64% to 116,338 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 128d
  Chief Financial Officer Sullivan Timothy Eugene was granted 58,140 shares, increasing direct ownership by 62% to 152,041 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 128d
  General Counsel Watson David O. was granted 55,986 shares, increasing direct ownership by 63% to 144,517 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 128d
  Chief Executive Officer Francois Cedric was granted 195,952 shares, increasing direct ownership by 69% to 481,997 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 135d
  Chief Medical Officer Baumal Caroline sold $60,878 worth of shares (2,797 units at $21.77), decreasing direct ownership by 3% to 86,527 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 135d
  VP/Chief Accounting Officer Chopas James George sold $44,924 worth of shares (2,064 units at $21.77), decreasing direct ownership by 4% to 49,805 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 135d
  Chief Business & Strat Officer Delong Mark Jeffrey sold $73,371 worth of shares (3,371 units at $21.77), decreasing direct ownership by 4% to 78,353 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 135d
  Chief Scientific Officer Deschatelets Pascal sold $129,025 worth of shares (5,928 units at $21.77), decreasing direct ownership by 0.51% to 1,151,382 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 135d
  Chief Executive Officer Francois Cedric sold $591,845 worth of shares (27,192 units at $21.77), decreasing direct ownership by 9% to 286,045 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 135d
  Chief Technical Officer Nicholson Nur sold $168,138 worth of shares (7,725 units at $21.77), decreasing direct ownership by 10% to 71,118 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 135d
  Chief Financial Officer Sullivan Timothy Eugene sold $223,901 worth of shares (10,287 units at $21.77), decreasing direct ownership by 10% to 93,901 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 135d
  General Counsel Watson David O. sold $170,467 worth of shares (7,832 units at $21.77), decreasing direct ownership by 8% to 88,531 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 137d
  Chief Medical Officer Baumal Caroline sold $37,250 worth of shares (1,882 units at $19.79), decreasing direct ownership by 2% to 89,324 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 137d
  VP/Chief Accounting Officer Chopas James George sold $14,370 worth of shares (726 units at $19.79), decreasing direct ownership by 1% to 51,869 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 137d
  Chief Business & Strat Officer Delong Mark Jeffrey sold $26,404 worth of shares (1,334 units at $19.79), decreasing direct ownership by 2% to 81,724 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 137d
  Chief Scientific Officer Deschatelets Pascal sold $17,992 worth of shares (909 units at $19.79), decreasing direct ownership by 0.08% to 1,157,310 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 137d
  Chief Executive Officer Francois Cedric sold $161,946 worth of shares (8,182 units at $19.79), decreasing direct ownership by 3% to 313,237 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 137d
  Chief Technical Officer Nicholson Nur sold $43,604 worth of shares (2,203 units at $19.79), decreasing direct ownership by 3% to 78,843 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 137d
  Chief Financial Officer Sullivan Timothy Eugene sold $57,241 worth of shares (2,892 units at $19.79), decreasing direct ownership by 3% to 104,188 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 137d
  General Counsel Watson David O. sold $48,987 worth of shares (2,475 units at $19.79), decreasing direct ownership by 3% to 96,363 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 143d
  VP/Chief Accounting Officer Chopas James George sold $19,369 worth of shares (873 units at $22.19), decreasing direct ownership by 2% to 52,595 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 143d
  Chief Business & Strat Officer Delong Mark Jeffrey sold $39,493 worth of shares (1,780 units at $22.19), decreasing direct ownership by 2% to 83,058 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 143d
  Chief Scientific Officer Deschatelets Pascal sold $50,520 worth of shares (2,277 units at $22.19), decreasing direct ownership by 0.20% to 1,158,219 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 143d
  Chief Executive Officer Francois Cedric sold $225,999 worth of shares (10,186 units at $22.19), decreasing direct ownership by 3% to 321,419 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 143d
  Chief Technical Officer Nicholson Nur sold $58,086 worth of shares (2,618 units at $22.19), decreasing direct ownership by 3% to 81,046 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 143d
  Chief Financial Officer Sullivan Timothy Eugene sold $85,554 worth of shares (3,856 units at $22.19), decreasing direct ownership by 3% to 107,080 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 143d
  General Counsel Watson David O. sold $128,242 worth of shares (5,780 units at $22.19), decreasing direct ownership by 6% to 98,838 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 149d
  General Counsel Watson David O. exercised 888 shares at a strike of $14.95, increasing direct ownership by 0.86% to 104,618 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 152d
  Chief Medical Officer Baumal Caroline sold $77,097 worth of shares (3,020 units at $25.53), decreasing direct ownership by 3% to 91,206 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
• 153d
  Director Machiels Alec was granted 7,961 shares, increasing direct ownership by 2% to 384,989 units (SEC Form 4)

  4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

Other APLS categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends